Results 81 to 90 of about 141,477 (341)
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]
, 2018 © The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast +66 more
core +2 more sources
Circulation, 2019 Owing to the differential propensity for bleeding and ischemic events with response to antiplatelet therapy, the safety and effectiveness of potent P2Y12 inhibitor ticagrelor in East Asian populations remain uncertain.
Duk‐Woo Park +18 more
semanticscholar +1 more source
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Arthritis &Rheumatology, EarlyView.Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
New England Journal of Medicine, 2005 BACKGROUND A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and
M. Sabatine +11 more
semanticscholar +1 more source
Ендоваскулярна нейрорентгенохірургія, 2020 Objective – to study the result of light transmission aggregometry with ADP for platelet reactivity before and after clopidogrel administration before extra-intracranial stenting. Materials and methods.
D.V. Shchehlov +3 more
doaj +1 more source
Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]
, 2018 © The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez +41 more
core +2 more sources
Atorvastatin–Clopidogrel Interaction [PDF]
Circulation, 2003 To the Editor: We read with some fascination the paper by Lau et al1 exploring the possibility of an interaction between atorvastatin and clopidogrel. Unfortunately, the authors do not make clear whether the patients in the first study received aspirin, which would be the normal standard of care in patients undergoing percutaneous coronary ...
Russell A. Denman, Paul T. Martin
openaire +3 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims We estimate trends in severe drug–drug interaction (DDI) prevalence and examine longitudinal associations between DDI exposure and health outcomes (emergency department [ED] visits, quality‐of‐life [QoL] and functional decline) over approximately 10‐years in the older community‐dwelling population in Ireland.
John E. Hughes +2 more
wiley +1 more source
A survey of Top 200 Drugs—Inconsistent Practice of Drug Strength Expression for Drugs Containing Salt Forms [PDF]
, 2012 Many ionizable drugs are developed and marketed as salt forms. However, there are no clear US regulatory guidelines on drug strength labeling for salts. The strengths of some drugs are expressed as salts and some as free acids/bases.
Prohotsky, Daniel, Zhao, Fang
core +2 more sources
Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y<sub>12</sub> Inhibitor Prescribing. [PDF]
Clin Pharmacol TherP2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Springer AN +14 more
europepmc +2 more sources